Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 28, 2022

Adjuvant Nivolumab After Salvage Surgery for Recurrent Head and Neck SCC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase 2 trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck
Clin. Cancer Res 2022 Jun 02;[EPub Ahead of Print], JL Leddon, S Gulati, S Haque, C Allen, S Palackdharry, M Mathews, N Kurtzweil, MK Riaz, V Takiar, M Nagasaka, Y Patil, C Zender, A Tang, B Cervenka, J McGrath, WM Korn, BH Hinrichs, R Jandarov, N Harun, A Sukari, TM Wise-Draper

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading